The Central Drugs Standard Control Organization (CDSCO) panel has endorsed the continuation of Serum Institute of India’s (SII) phase-II clinical trial for its dengue vaccine. This decision follows positive outcomes observed during the phase-I interim clinical trial.

The phase-I trial, conducted in Australia, involved 60 healthy individuals aged 18 to 45 years. It was a double-blind, randomized, placebo-controlled study aimed at assessing the safety and immunogenicity of SII’s tetravalent live attenuated dengue vaccine.

Serum Institute, collaborating with the National Institute of Allergy and Infectious Diseases (NIAID) and the National Institutes of Health (NIH) in the USA, developed the vaccine using strains provided by NIAID.

The recommendation by the CDSCO panel marks a significant step forward in the development of a potentially effective dengue vaccine, crucial for combating the disease’s spread and impact globally.

For more updates on this development, stay tuned to reliable health news sources and regulatory updates from CDSCO.